Positive Interim Results Demonstrating Durable Responses in Ongoing Ph 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC Announced April 30, 2025
New long-term PFS data projections reinforce SC DARZALEX quadruplet therapy as a foundational SoC for patients with newly diagnosed multiple myeloma April 30, 2025
TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC April 30, 2025
TAR-200 monotherapy demonstrates highest CRR reported to date with sustained clinical benefits in patients with certain types of bladder cancer April 30, 2025
Trodelvy + Keytruda Demonstrate Statistically Significant PFS Improvement in Patients With 1L PD-L1+ Metastatic TNBC April 30, 2025
OLYMPUS Long-Term Follow-Up shows Nearly 4-Year DoR in Patients with LG-UT Urothelial Cancer Who Achieved a Complete Response to prior JELMYTO Treatment April 30, 2025
Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec announced April 30, 2025
FAILED TRIAL: ASPEN-03 and ASPEN-04 Ph 2 Trials of Evorpacept + Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints April 30, 2025
Interim OS Analysis Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab vs Keytruda in PD-L1+ve Advanced NSCLC from HARMONi-2 Study April 30, 2025
EMA gives IMPD approval to initiate Ph 1 trial of OT-C001 + Rituximab in DLBCL patients April 30, 2025
FDA Clears IND Application for Ph 2 Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer April 30, 2025
MHRA grants conditional marketing authorisation for AUCATZYL (obecabtagene autoleucel) for the treatment of adult patients with R/R B-ALL April 30, 2025
Ivonescimab Receives NMPA Approval for 1L Treatment of PD-L1-Positive NSCLC, Based on Ph 3 Trial Demonstrating Superior Efficacy Over Keytruda April 30, 2025
